We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00283790
First Posted: January 30, 2006
Last Update Posted: April 3, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sanofi
  Purpose
Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator

Condition Intervention Phase
Insomnia Drug: zolpidem tartrate Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Investigation of Psycliomotor and Cognitive Residual Effects After Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopielone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Plurazepam 30 mg As An External Comparator

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Psychometric testing:
  • Critical Flicker Fusion (CFF)
  • Choice Reaction Time (CRT)
  • Immediate and Delayed Recall of Supraspan Word Lists (WRI and WRD)
  • Compensatory Tracking Task (CTT)
  • Digit Symbol Substitution Test (DSST)

Secondary Outcome Measures:
  • Efficacy Measures:
  • Sleep measures from Morning Sleep Questionnaire
  • Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
  • Leeds Sleep Evaluation Questionnaire (LSEQ)
  • Bond & Lader (B&L) Visual Analog Scale
  • Health Outcome Measures
  • Sleep Treatment Questionnaire

Estimated Enrollment: 36
Study Start Date: January 2006
Estimated Study Completion Date: April 2006
Detailed Description:
This is a crossover study, with 4 different treatments (Ambien, Lunesta, placebo, and flurazepam). The flurazepam arm always comes last due to the long washout period associated with it. The other 3 arms are randomized.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA:

  1. Healthy male and female subjects aged between 18 and 45 years.
  2. Usual bedtime between 21:00 and 01:00
  3. Body mass index (BMI) between 18 and 32 kg/m2.
  4. Certified as healthy by a comprehensive clinical assessment (detailed medical history and a complete physical examination).
  5. Laboratory tests within the normal range of the laboratory (hematology, biochemistry, urinalysis) or within the acceptable range per agreement between investigator and sponsor.
  6. Negative urine pregnancy test for females (to be confirmed at screening and prior to every dose of study medication)
  7. Women must use a medically acceptable form of contraception (steroidal contraceptive, double-barrier, or intra-uterine device) during the entire study period, or they must be surgically sterilized or post-menopausal. If abstinent, women must agree to use double-barrier contraception throughout the study period should they become sexually active.
  8. Written informed consent signed

EXCLUSION CRITERIA:

  1. Presence or history of clinically relevant cardiovascular, hepatic, pulmonary, gastrointestinal, renal, metabolic, hematological, neurologic or psychiatric disease, any acute infectious disease or signs of acute illness, and myasthenia gravis
  2. Any disorder initiating or maintaining sleep such as Obstructive Sleep Apnea, Insomnia, Restless Leg Syndrome, Periodic Limb Movement Disorder, Circadian Rhythm Disorder and Parasomnia
  3. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).
  4. Symptomatic hypotension, whatever the decrease of blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position.
  5. History of hypersensitivity to zolpidem, eszopiclone, or flurazepam.
  6. Use of any medication within one month prior to study start, except occasional use of acetaminophen or ibuprofen.
  7. History of drug abuse during prior twelve months
  8. Excessive consumption of xanthine-based beverages (more than 6 cups or glasses per day) or unable to stop consumption during the overnight study periods.
  9. Inability to communicate or cooperate with the investigator because of a language problem, poor mental status, or impaired cerebral status.
  10. Positive results of urine drug screen testing (amphetamines, benzodiazepines, cannabis, barbiturates, cocaine, opiates, antidepressants).
  11. Any use of dietary, herbal, and/or fitness/body-building supplements (with the exception of vitamins)
  12. Current use of tobacco products including cigarettes, cigars, pipes, or chewing tobacco, current participation in a smoking cessation program, or discontinuation of smoking within 3 months prior to screening
  13. Subject is currently participating in another clinical trial with an investigation product/device (or within 30 days of screening).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00283790


Locations
United States, New Jersey
Sanofi-Aventis
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Phyllis Diener Sanofi
  More Information

ClinicalTrials.gov Identifier: NCT00283790     History of Changes
Other Study ID Numbers: PM_L_0289
First Submitted: January 27, 2006
First Posted: January 30, 2006
Last Update Posted: April 3, 2008
Last Verified: April 2008

Additional relevant MeSH terms:
Zolpidem
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action